Risk factors

Lisata Therapeutics faces continuous net losses and significant future capital needs to fund ongoing clinical trials. The company depends on the clinical success and commercialization of its lead product candidate, certepetide. Operations rely heavily on third-party contract manufacturers and foreign research collaborations without internal commercial infrastructure.

Life Time Group faces heavy leverage with $1,556 million in total debt and $148 million in net interest expense. Growth relies on executing an asset-light expansion model while managing high construction costs and interest rates. Operations are sensitive to member retention, variable interest rates, and extensive regulatory compliance.

LSB Industries faces significant risks regarding the cost and availability of natural gas and other key raw materials.

Cyclicality and raw material price volatility drive earnings fluctuations and asset impairment risks.

This initial risk section is dominated by operational, international, and integration challenges stemming from the merger of SWM and Neenah.

Reliance on National subsidiary dividends and cash flow dominates the holding company risk profile.

Moelis & Co's risk factors are dominated by dependence on key investment banking talent, advisory fee volatility, and intense competitive pressures.

Medalist Diversified faces significant concentration risk with a small property portfolio and a $30.5M cumulative net loss to date. Future growth depends on securing additional capital and competing for commercial real estate acquisitions. Operations are heavily exposed to tenant creditworthiness, particularly middle-market businesses.

Commercial real estate transaction volumes are exposed to macroeconomic volatility, interest rate shifts, and hybrid work trends. Brokerage revenue relies heavily on discretionary fees, seasonal trends, and key producer retention. Extensive reliance on independent contractors and geographic exposure, particularly in California, heighten operating risks.

Refining margin volatility and climate-related regulatory pressures dominate Marathon Petroleum's risk profile, alongside extensive operational hazards.

MPLX faces risks primarily driven by producer well declines, reliance on Marathon Petroleum Corporation (MPC), extensive environmental and safety regulations, and debt obligations totaling $21.2 billion.

Concentrated reliance on a single foundry, GLOBALFOUNDRIES Singapore, for wafer manufacturing and advanced MTJ technology and STT-MRAM development. Significant customer concentration with a small group of buyers driving a large portion of revenues. Financial dependence on ongoing capital raises and revenue growth amid historical operating losses of $50.4 million in 2024.